FDA approves avelumab plus axitinib for renal cell carcinoma

On May 14, 2019, the Food and Drug Administration approved avelumab (BAVENCIO ®, EMD Serono, Inc.) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC).
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news